Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-221-5 | CAS number: 7790-76-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- No data
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- publication
- Title:
- A 90-day subchronic toxicity study of beta-calcium pyrophosphate in rat
- Author:
- Lee JH, Chang B-S, Ryu H-S & Lee C-K
- Year:
- 2 009
- Bibliographic source:
- Drug and Chemical Toxicology, 32(3): 277-282
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: ISO 10993 Biological Evaluation of Medical Devices Part II (1995): test for systemic/6.7 subchronic oral application
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1998
- Deviations:
- yes
- Remarks:
- only one dose tested at 30 mg/kg bw/day, no immulogoical or neurological effects examined
- Principles of method if other than guideline:
- Evaluation of toxicity from subchronic oral administration of β-calcium pyrophosphaste to male and female Sprague-Dawley rats.
- GLP compliance:
- not specified
- Limit test:
- yes
Test material
- Reference substance name:
- Dicalcium pyrophosphate
- EC Number:
- 232-221-5
- EC Name:
- Dicalcium pyrophosphate
- Cas Number:
- 7790-76-3
- Molecular formula:
- Ca2O7P2
- IUPAC Name:
- dicalcium pyrophosphate
- Reference substance name:
- Beta calcium pyrophosphate
- IUPAC Name:
- Beta calcium pyrophosphate
- Test material form:
- other: aqueous extract of beta calcium pyrophosphate
- Details on test material:
- β-calcium pyrophosphate (β-CPP) was prepared by reacting high-purity Ca2P2O7 (Sigma-Aldrich Co, St Louis, Missouri, USA; 99.99 %;) with CaCO3 (High Purity Chemicals, Sakado, Japan; 99.99 %) in the solid state. Porous β-CPP was prepared by using polyurethane foams with randomly interconnected pores (60 ppi). Polyurethane foams were coated with β-CPP slurry and then burned and sintered at 1,100 to 1,300°C for 2 hours. The resulting porous β-CPP contained interconnected pores (pore size 300-500 μm) and a porosity of 80%, which is similar to that of natural spongy bone.
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dae Han Biolink Inc, ChoongChung-BukDo, Korea
- Age at study initiation: 5 weeks
- Weight at study initiation: 182 ± 8 g (treated males); 163 ±7 g (treated females); 183 ± 8 g (control males); 163 ± 6 g (control females)
- Fasting period before study: No
- Housing: metal cages
- Diet (e.g. ad libitum): γ-irradiated (25-40 kGy; Greenpai, Yugookun, Korea) commercial feed (Purina feed for rats; Nestle Purina Pet Care Co, St Louis, USA)
- Water (e.g. ad libitum): autoclaved (121 °C for 15 min)
- Acclimation period: 7 days in individual cages
ENVIRONMENTAL CONDITIONS
- Temperature: 20-24°C
- Humidity: 45-50%
- Air changes (per hr): room air turnaround was 12-18 times/hour
- Photoperiod (hrs dark / hrs light): 12 hours light (07:00 to 19:00) and 12 hours dark
IN-LIFE DATES: From: Day minus 7 To: Day 90
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- other: saline
- Details on oral exposure:
- Aqueous extracts for the administration experiments were prepared by dissolving 0.1026 g of β-CPP in 34.2 mL of saline at 70 ± 2°C for 24 hours.
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Daily between 10:00 am and 12:00 am
Doses / concentrations
- Dose / conc.:
- 30 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 males and 10 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: maximum required dose for repeated dose toxicity studies regarding biological evaluation of medical devices
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Not specified
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily during the treatment period to detect mortality, morbidity and signs of toxicity
BODY WEIGHT: Yes
- Time schedule for examinations: at baseline and then weekly until scheduled sacrifice 90 days later
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Not specified
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: at baseline and towards the end of the treatment period.
- Dose groups that were examined: all rats
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on day 90
- Anaesthetic used for blood collection: not specified
- Animals fasted: Not specified
- How many animals: all
- Parameters examined: red blood cell count (RBC, white blood cell count (WBC), haemaglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular haemaglobin (MCH), mean corpuscular haemaglobin concentration (MCHC) and platelet count, prothrombin times (PTs) and activated partial thromboplastin time (aPTT), differential blood cell counts (i.e of lymphocytes, neutrophils, basophils, eosinophils and monocytes
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on day 90
- Animals fasted: Not specified
- How many animals: all
- Parameters examined: total protein, albumin, glucose, total cholesterol, triglyceride (TG), total bilirubin, blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), Cl, Ca, K and P
URINALYSIS: Yes
- Time schedule for collection of urine: no data
- Metabolism cages used for collection of urine: Not specified
- Animals fasted: Not specified
- Parameters examined: urine color, Specific gravity (SG), pH, leukocyte esterase, nitrate, protein, glucose, ketone bodies, urobilinogen and bilirubin, and occult blood
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No
- Sacrifice and pathology:
- - On day 90, all animals were anaethetised with ether, euthanised by exsanguination, weighed, and blood samples were collected from abdominal aorta for haematology and serum biochemistry.
- Each animal was subjected to complete necropsy including external body macroscopic examinations.
- The weights of heart, liver, lung, kidney (both), spleen, adrenal glands (both), brain, thymus, pituitary gland, testes (both) and ovaries (both) were determined.
- Organ-to-body-weight and organ-to-brain-weight ratios were calculated.
- At sacrifice, samples of the tissues and organs listed above, and all gross lesions, were fixed and preserved in 10% neutral buffered formalin.
- Tissue samples from all animals were further processed for histopathology. The following tissues and organs were sectioned at 2 μm and H&E (haematoxylin and eosin) stained: digestive system (oesophagus, stomach, duodenum, jejunum, ileum, caecum, colon, liver, gall bladder, salivary gland and pancreas); urinary system (kidney and urinary bladder); respiratory system (lung and trachea); cardiovascular system (heart and aorta); haematopoietic system (spleen, thymus, lymph nodes and bone marrow); endocrine system (adrenal, pituitary, thyroid and parathyroid glands); nervous system (brain and spinal cord); muscular skeletal system (skeletal muscle, femur and sternum); male reproductive system (testes, epididymides, prostate and seminal vessel); female reproductive system (ovaries, uterus, mammary glands and vagina), skin, tongue and eyes. - Statistics:
- Mean and statistical deviations were calculated for all quantitative data. If warranted, and based on group size constraints, the test and control groups were compared by using one-way analysis of variance, followed by the Dunnett's multiple comparison test. Homogeneity of variances was tested using Bartlett's test and, when differences were significant (P<0.05), the Kruskal-Wallis test was performed. When those results were significant, the Wilcoxon-Mann-Whitney rank-sum test and the Nemenye-Kruskal-Wallis multiple comparisons were performed. The Chi-square test was used to determine the significances of histopathological changes.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- β-CPP and control group animals gained weight equally over the treatment period (see Table 1, attached)
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- no treatment-related abnormalities in treated or control animals during the test period
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Activated partial thromboplastin time (aPTT) showed significantly decreased values in female rats. But these values were all in the range of the reference values and are therefore considered as normal and not treatment-related.
For detailed information see Table 2_1 in "any other information on results" and Table 2 (attached). - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Cholesterol and AST (GOT) showed significantly decreased values in female rats and Cloride ions were significantly increased in males But these values were all in the range of the reference values and are therefore considered as normal and not treatment-related.
For detailed information see Table 2_1 in "any other information on results" and Table 2 (attached). - Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- - No mortalities occurred during the study, and no clinical signs or behavioural or motor activity changes were observed that could have been attributed to treatment.
- No diet-related effects on feed intake were observed.
- No statistically significant differences in mean body weight gain (see Table 1, attached) or mean feed efficiency were observed between the β-CPP and control groups, or between male and female rats in the two groups.
- No significant differences were observed between β-CPP and control males or females in terms of urinalysis response variables by random sampling.
- Mean serum chloride level in β-CPP-treated males (104 ± 1) was significantly higher (P = 0.026) than in controls (102 ± 2).
- Mean aPTT, cholesterol and AST(GOT) levels in β-CPP females (25.5 ± 3; 102 ± 18 and 133 ± 34 respectively) were significantly lower (P = 0.021, P = 0.049 and P = 0.026 respectively) than in control females (28.1 ± 2.0; 112 ± 11 and 170 ± 21). However, the four parameters were within the normal range in both female subgroups (see Table 2, attached).
- No differences were observed between β-CPP and control groups with respect to other haematologic response and response variables.
- No differences were found between the two study groups or between males and females in these groups with respect to absolute or relative organ weights (see Table 3, attached)
- Microscopic histopathology revealved no evidence of changes that could be attributed to β-CPP treatment. All observed findings were typical for the Sporague-Dawley strain.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- > 30 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: no effects observed
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
Table 2_1: Significant differences in hematology and biochemical values of male and female rats |
||||
|
RV |
Control |
Treated |
p-value |
Female rats |
||||
aPTT (seconds) |
18.4-45 |
28.1±2.0 |
25.5±3.0 |
0.0210* |
Cholesterol (mg/dL) |
40-130 |
112±11 |
102±18 |
0.0491* |
AST (GOT) (IU/L) |
47-155 |
170±21 |
133±34 |
0.0256* |
Male rats |
||||
Cloride (mmol/L) |
98-110 |
102±2 |
104±1 |
0.0262* |
RV = reference value * groups significantly different (p<0.05) by the one-way analysis of variance test or the Wilcoxon rank-sum test. |
Applicant's summary and conclusion
- Conclusions:
- No adverse effects were detected in male or female rats when β-calcium pyrophosphate was fed orally at 30 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.